ArticleClinical transplantation2026
Evaluation of Global Immune Biomarkers to Predict Infections in Lung Transplant Recipients.
Article in Clinical transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluation of Global Immune Biomarkers to Predict Infections in Lung Transplant Recipients.Clinical transplantation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundImmune biomarkers could assess levels of immunosuppression and predict infections in transplant recipients. We aimed to evaluate the absolute lymphocyte count (ALC), absolute neutrophil count (ANC), Quantiferon-Monitor and the mitogen component of the Quantiferon-CMV assay alone and combined to predict serious opportunistic infections (SOI) in lung transplant recipients.
methodsPatients were prospectively recruited from 2015-17, with blood collected at 3, 6 and 12 months post-transplant. Infections were classified as SOI if requiring hospitalization and caused by an opportunistic pathogen. Logistic regression was used to calculate odds ratios (OR).
resultsWithin 18 months post-transplant, 35/80 patients experienced 46 SOI's. Low ALCs were associated with SOI between 3-6 (median 1.4 vs. 1.0×1000 cells/µL, OR 5.38 per unit decrease, 95% CI 1.38-21.02, p = 0.02) and 6-12 (1.3 vs. 0.8×1000 cells/µL, OR 3.48, 95% CI 1.20-10.1, p = 0.02) months. Mitogen values were significantly lower with SOI between 3-6 months (5.8 vs. 0.3 IU/mL, OR 0.78, 95% CI 0.63-0.97, p = 0.02). Area under the ROC curve for all biomarkers combined were modestly higher compared to ALC alone. Negative predictive values were high.
conclusionsImmune biomarkers have the potential to measure net immunosuppression and identify transplant recipients at higher risk for SOI. ALC was the most useful single test although incorporating 3 other biomarkers modestly improved predictions. Negative predictive values were high indicating that patients with high ALC values were unlikely to experience SOI. While this approach could inform decision-making regarding immunosuppression dosing, intensity of monitoring and antimicrobial prophylaxis, further research is required before clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.